Navigation Links
Arthrosurface Raises $4 Million of Preferred Equity Financing
Date:2/28/2008

FRANKLIN, Ma., Feb. 28 /PRNewswire-FirstCall/ -- Arthrosurface, Inc. (http://www.arthrosurface.com), the developer of less-invasive joint resurfacing systems, has announced that it has raised approximately $4 million in its latest Preferred Stock Series F equity financing. Funded by Boston Millennia Partners and private investors, to date, the company has raised approximately $31 million of equity capital. "The Series F funding is earmarked to support our new product launches, expansion of the company's direct field sales team and to provide ongoing working capital," said Steve Ek, COO. "We now have greater resources to provide for the people and working capital to support the continued growth of the business."

Arthrosurface is entering its fourth year of commercial launch with approximately 7,000 devices implanted by more than 2,000 surgeon users in the various joint applications of the HemiCAP(R) system. Last year, US implant sales were up 55% with strong growth across all key product lines. In particular, sales of the company's first US knee device, the Patello-Femoral HemiCAP(R), grew 237% year on year. "We have found that within the first year of clinical launch, implanting surgeons closely monitor patient progress and, once they have confirmed positive results, sales begin to rise significantly. An excellent example of this was our great toe product. Cases went from a few hundred in the first year to thousands within two years. We expect similar adoption with the release of our new products," commented company president Steve Tallarida.

The company's HemiCAP(R) systems consist of a range of contoured articular prosthetics and instrumentation intended for the repair of significant lesions and cartilage damage in the major joints. Arthrosurface continues to grow its line of shoulder, great toe, patello-femoral and hip products in the US. These same products are sold in Europe in addition to its knee femoral condyle and talar dome devices.

The HemiCAP(R) system provides a less invasive alternative servicing the joint reconstruction market with its resurfacing systems. "We believe there is a growing body of patients that have damaged cartilage seeking medical options that will enable them to maintain their active lifestyles. These patients will consider surgical treatment provided that recovery is relatively easy and their future medical options remain open. We believe that this is the new Millennium Patient(TM)," said Lester Fehr, VP Sales & Marketing. "Today's patient is a more demanding and educated consumer. For Arthrosurface, we believe that this is our patient."


'/>"/>
SOURCE Arthrosurface, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
2. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
3. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
4. Primera Biosystems Raises $21 Million in Series B Private Round
5. Cellectar, Inc. Raises $13 Million in Private Offering
6. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
7. Anesiva Raises $45 Million in Common Stock Offering
8. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
9. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
10. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
11. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... VA (PRWEB) , ... February 06, 2016 , ... The ... session, cost-free, for middle and high school teachers on Wednesday February 10, 2016. ... held at the Smithsonian-Mason School of Conservation, located at 1500 Remount Road in Front ...
(Date:2/5/2016)... 2016 Amarantus BioScience Holdings, Inc. ... on developing products for Regenerative Medicine, Neurology and Orphan ... Designation (RPDD) from the US Food and Drug Administration ... was previously granted orphan drug designation (ODD) by the ... BioScience Holdings, Inc. (OTCQB: AMBS), a ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments ... host live demos and poster sessions, and present on the analysis of mycotoxins ... place March 6 to 10 at the Georgia World Congress Center in Atlanta, ...
(Date:2/4/2016)... , February 4, 2016 ... a biotechnology acceleration company is pleased to provide the following ... --> Over the last 3 months we have ... securities purchase agreements exceeding $1,000,000. As a result, we have ... Mannin Research Inc. license agreement and expect that development to ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ... "Emotion Detection and Recognition Market by ... Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020" report ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition of ...
(Date:2/2/2016)...   Parabon NanoLabs (Parabon) announced today ... Office and the Defense Forensics and Biometrics Agency ... company,s Snapshot Kinship Inference software for ... defense-related DNA forensics.  Although Snapshot is best known ... ancestry from DNA evidence), it also has the ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
Breaking Biology News(10 mins):